Table 2

An overview of the latest studies using CAR-Ms in cancer therapy. Macrophages types, targets, cancer subtypes and significant findings are summarized

CAR-M targetMacrophage source/typeTested cancer models (cell lines)In vivo modelStudy findingsReference
In vitroIn vivo
CD19
HER2
Mesothelin
Human monocytic cell line (THP-1)
Human primary macrophages (CD14+ peripheral blood)
SKOV3 (ovarian cancer)
HTB-20 (breast cancer)
CRL-2351 (breast cancer)
NOD/SCID mice bearing SKOV3Antigen-specific phagocytosis and tumor clearanceDecreased tumor burden and prolonged overall survival24
CD19
CD22
Murine bone marrow-derived macrophages (BMDM,C57BL/6J)
Murine macrophages
(J774A.1)
Raji B cellsReduced cancer cell number by 40%23
HER2Murine macrophages (Raw264.7 cells)4T1 (breast cancer)BALB /C mice bearing 4T1No effect on cancer growthSignificant inhibition of tumor growth74
HER2Murine bone marrow-derived macrophagesCT-26
(Murine colon carcinoma)
AU-565 human breast cancer cells
BALB /C mice engrafted with CT26-HER2+alone/ with CT-26 wild typeDose-dependent eradication of AU-565 and CT-26
Cancer cells
Single tumor model: tumor regression
Dual model:
Abscopal effect
Epitope spreading
73
CCR7Murine macrophages (Raw264.7 cells)4T1 (breast cancer)BALB /C mice bearing 4T1Suppressed tumor growth.
Prolonged survival
75
CD19
Mesothelin
Induced pluripotent stem cell-derived, CAR-expressing macrophage cells (CAR-iMac)K562 (chronic myeloid leukemia)
OVCAR3 (ovarian cancer)
ASPC1 (pancreatic cancer)
NSG mice bearing ovarian cancer (HO8910)Antigen-dependent phagocytosis; anticancer cell functionsTumor burden reduction76
  • CAR-Ms, CAR macrophages.